Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Citrocil
2. Dihydrostreptomycin
3. Sulfate, Dihydrostreptomycin
1. Dihydrostreptomycin Sesquisulfate
2. 5490-27-7
3. Dihydrostreptomycin Sulphate
4. Dihydrostreptomycin Sulfate [usp]
5. Dihydrostreptomycin Sulfate (2:3)(salt)
6. T7d4876iue
7. Didromycin
8. Nsc-756739
9. Didromycine
10. Panstreptin
11. 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric Acid
12. Dihydrostreptomycin Sulfate (usp)
13. Hydroxycyclohexyl]guanidine;sulfuric Acid
14. Dihydrostreptomycin 3/2 Sulfate
15. Dihydrostreptomyzinsulfat
16. Einecs 226-823-7
17. Unii-t7d4876iue
18. Ai3-50133
19. Dihydrostreptomycin Sequisulphate
20. Dihydrostreptomycinium Sulfuricum
21. 1-[(1r,2r,3s,4r,5r,6s)-3-carbamimidamido-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-tri
22. Ncgc00094655-01
23. Cas-5490-27-7
24. Dsstox_cid_25824
25. Dsstox_rid_81155
26. Dsstox_gsid_45824
27. Chembl3188576
28. Dtxsid6045824
29. Tox21_111309
30. Mfcd00070252
31. Akos026750384
32. Akos037515800
33. D-streptamine, O-2-deoxy-2-(methylamino)-.alpha.-l-glucopyranosyl-(1.fwdarw.2)-o-5-deoxy-3-c-(hydroxymethyl)-.alpha.-l-lyxofuranosyl-(1.fwdarw.4)-n,n'-bis(aminoiminomethyl)-, Sulfate (2:3) (salt)
34. D-streptamine, O-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1-2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1-4)-n,n'-bis(aminoiminomethyl)-, Sulfate (2:3) (salt)
35. Dihydrostreptomycin Sulfate [mart.]
36. Dihydrostreptomycin Sulfate [usp-rs]
37. Dihydrostreptomycin Sulfate [who-dd]
38. Dihydrostreptomycin Sesquisulfate [mi]
39. 1425-61-2
40. D02512
41. Dihydrostreptomycin Sulfate [green Book]
42. Dihydrostreptomycin Sulfate [usp Monograph]
43. Dihydrostreptomycin Sulphate (2:3)(salt)
44. W-105598
45. Q27289765
46. Dihydrostreptomycin Sulfate, Antibiotic For Culture Media Use Only
47. 1,1'-((1r,2r,3s,4r,5r,6s)-4-(((2r,3r,4r,5s)-3-(((2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)tetrahydro-2h-pyran-2-yl)oxy)-4-hydroxy-4-(hydroxymethyl)-5-methyltetrahydrofuran-2-yl)oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl)diguanidine Sesquisulfate
48. D-streptamine, O-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1->2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1->4)-n1,n3-bis(aminoiminomethyl)-, Sulfate (2:3)
49. D-streptamine, O-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1.fwdarw.2)-o-5-deoxy-3-c-(hydroxymethyl)-alpha-l-lyxofuranosyl-(1.fwdarw.4)-n,n'-bis(aminoiminomethyl)-, Sulfate (2:3) (salt)
Molecular Weight | 1461.4 g/mol |
---|---|
Molecular Formula | C42H88N14O36S3 |
Hydrogen Bond Donor Count | 32 |
Hydrogen Bond Acceptor Count | 42 |
Rotatable Bond Count | 18 |
Exact Mass | 1460.4647787 g/mol |
Monoisotopic Mass | 1460.4647787 g/mol |
Topological Polar Surface Area | 928 Ų |
Heavy Atom Count | 95 |
Formal Charge | 0 |
Complexity | 993 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 30 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 5 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Dihydrostreptomycin sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dihydrostreptomycin sulfate, including repackagers and relabelers. The FDA regulates Dihydrostreptomycin sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dihydrostreptomycin sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dihydrostreptomycin sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dihydrostreptomycin sulfate supplier is an individual or a company that provides Dihydrostreptomycin sulfate active pharmaceutical ingredient (API) or Dihydrostreptomycin sulfate finished formulations upon request. The Dihydrostreptomycin sulfate suppliers may include Dihydrostreptomycin sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Dihydrostreptomycin sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dihydrostreptomycin sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dihydrostreptomycin sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dihydrostreptomycin sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dihydrostreptomycin sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dihydrostreptomycin sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dihydrostreptomycin sulfate suppliers with NDC on PharmaCompass.
Dihydrostreptomycin sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dihydrostreptomycin sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dihydrostreptomycin sulfate GMP manufacturer or Dihydrostreptomycin sulfate GMP API supplier for your needs.
A Dihydrostreptomycin sulfate CoA (Certificate of Analysis) is a formal document that attests to Dihydrostreptomycin sulfate's compliance with Dihydrostreptomycin sulfate specifications and serves as a tool for batch-level quality control.
Dihydrostreptomycin sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Dihydrostreptomycin sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dihydrostreptomycin sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Dihydrostreptomycin sulfate EP), Dihydrostreptomycin sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dihydrostreptomycin sulfate USP).
LOOKING FOR A SUPPLIER?